1 Market Overview of Hematologic Malignancies 1.1 Hematologic Malignancies Market Overview 1.1.1 Hematologic Malignancies Product Scope 1.1.2 Hematologic Malignancies Market Status and Outlook 1.2 Global Hematologic Malignancies Market Size Overview by Region 2016 VS 2021VS 2027 1.3 Global Hematologic Malignancies Market Size by Region (2016-2027) 1.4 Global Hematologic Malignancies Historic Market Size by Region (2016-2021) 1.5 Global Hematologic Malignancies Market Size Forecast by Region (2022-2027) 1.6 Key Regions, Hematologic Malignancies Market Size (2016-2027) 1.6.1 North America Hematologic Malignancies Market Size (2016-2027) 1.6.2 Europe Hematologic Malignancies Market Size (2016-2027) 1.6.3 Asia-Pacific Hematologic Malignancies Market Size (2016-2027) 1.6.4 Latin America Hematologic Malignancies Market Size (2016-2027) 1.6.5 Middle East & Africa Hematologic Malignancies Market Size (2016-2027) 2 Hematologic Malignancies Market Overview by Type 2.1 Global Hematologic Malignancies Market Size by Type: 2016 VS 2021 VS 2027 2.2 Global Hematologic Malignancies Historic Market Size by Type (2016-2021) 2.3 Global Hematologic Malignancies Forecasted Market Size by Type (2022-2027) 2.4 Leukemia 2.5 Lymphoma 2.6 Multiple Myeloma 2.7 Others 3 Hematologic Malignancies Market Overview by Application 3.1 Global Hematologic Malignancies Market Size by Application: 2016 VS 2021 VS 2027 3.2 Global Hematologic Malignancies Historic Market Size by Application (2016-2021) 3.3 Global Hematologic Malignancies Forecasted Market Size by Application (2022-2027) 3.4 Chemotherapy 3.5 Radiotherapy 3.6 Immunotherapy 3.7 Stem Cell Transplantation 3.8 Others 4 Hematologic Malignancies Competition Analysis by Players 4.1 Global Hematologic Malignancies Market Size by Players (2016-2021) 4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hematologic Malignancies as of 2020) 4.3 Date of Key Players Enter into Hematologic Malignancies Market 4.4 Global Top Players Hematologic Malignancies Headquarters and Area Served 4.5 Key Players Hematologic Malignancies Product Solution and Service 4.6 Competitive Status 4.6.1 Hematologic Malignancies Market Concentration Rate 4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data 5.1 Pfizer, Inc. 5.1.1 Pfizer, Inc. Profile 5.1.2 Pfizer, Inc. Main Business 5.1.3 Pfizer, Inc. Hematologic Malignancies Products, Services and Solutions 5.1.4 Pfizer, Inc. Hematologic Malignancies Revenue (US$ Million) & (2016-2021) 5.1.5 Pfizer, Inc. Recent Developments 5.2 F. Hoffmann-LA Roche ltd 5.2.1 F. Hoffmann-LA Roche ltd Profile 5.2.2 F. Hoffmann-LA Roche ltd Main Business 5.2.3 F. Hoffmann-LA Roche ltd Hematologic Malignancies Products, Services and Solutions 5.2.4 F. Hoffmann-LA Roche ltd Hematologic Malignancies Revenue (US$ Million) & (2016-2021) 5.2.5 F. Hoffmann-LA Roche ltd Recent Developments 5.3 Sanofi-Aventis 5.3.1 Sanofi-Aventis Profile 5.3.2 Sanofi-Aventis Main Business 5.3.3 Sanofi-Aventis Hematologic Malignancies Products, Services and Solutions 5.3.4 Sanofi-Aventis Hematologic Malignancies Revenue (US$ Million) & (2016-2021) 5.3.5 Bristol-Myers Squibb Company Recent Developments 5.4 Bristol-Myers Squibb Company 5.4.1 Bristol-Myers Squibb Company Profile 5.4.2 Bristol-Myers Squibb Company Main Business 5.4.3 Bristol-Myers Squibb Company Hematologic Malignancies Products, Services and Solutions 5.4.4 Bristol-Myers Squibb Company Hematologic Malignancies Revenue (US$ Million) & (2016-2021) 5.4.5 Bristol-Myers Squibb Company Recent Developments 5.5 AbbVie, Inc. 5.5.1 AbbVie, Inc. Profile 5.5.2 AbbVie, Inc. Main Business 5.5.3 AbbVie, Inc. Hematologic Malignancies Products, Services and Solutions 5.5.4 AbbVie, Inc. Hematologic Malignancies Revenue (US$ Million) & (2016-2021) 5.5.5 AbbVie, Inc. Recent Developments 5.6 Novartis AG 5.6.1 Novartis AG Profile 5.6.2 Novartis AG Main Business 5.6.3 Novartis AG Hematologic Malignancies Products, Services and Solutions 5.6.4 Novartis AG Hematologic Malignancies Revenue (US$ Million) & (2016-2021) 5.6.5 Novartis AG Recent Developments 5.7 GlaxoSmithKline PLC 5.7.1 GlaxoSmithKline PLC Profile 5.7.2 GlaxoSmithKline PLC Main Business 5.7.3 GlaxoSmithKline PLC Hematologic Malignancies Products, Services and Solutions 5.7.4 GlaxoSmithKline PLC Hematologic Malignancies Revenue (US$ Million) & (2016-2021) 5.7.5 GlaxoSmithKline PLC Recent Developments 5.8 Celgene Corporation 5.8.1 Celgene Corporation Profile 5.8.2 Celgene Corporation Main Business 5.8.3 Celgene Corporation Hematologic Malignancies Products, Services and Solutions 5.8.4 Celgene Corporation Hematologic Malignancies Revenue (US$ Million) & (2016-2021) 5.8.5 Celgene Corporation Recent Developments 5.9 Johnson & Johnson Services, Inc. 5.9.1 Johnson & Johnson Services, Inc. Profile 5.9.2 Johnson & Johnson Services, Inc. Main Business 5.9.3 Johnson & Johnson Services, Inc. Hematologic Malignancies Products, Services and Solutions 5.9.4 Johnson & Johnson Services, Inc. Hematologic Malignancies Revenue (US$ Million) & (2016-2021) 5.9.5 Johnson & Johnson Services, Inc. Recent Developments 5.10 Takeda Pharmaceutical Company limited 5.10.1 Takeda Pharmaceutical Company limited Profile 5.10.2 Takeda Pharmaceutical Company limited Main Business 5.10.3 Takeda Pharmaceutical Company limited Hematologic Malignancies Products, Services and Solutions 5.10.4 Takeda Pharmaceutical Company limited Hematologic Malignancies Revenue (US$ Million) & (2016-2021) 5.10.5 Takeda Pharmaceutical Company limited Recent Developments 6 North America 6.1 North America Hematologic Malignancies Market Size by Country (2016-2027) 6.2 United States 6.3 Canada 7 Europe 7.1 Europe Hematologic Malignancies Market Size by Country (2016-2027) 7.2 Germany 7.3 France 7.4 U.K. 7.5 Italy 7.6 Russia 7.7 Nordic 7.8 Rest of Europe 8 Asia-Pacific 8.1 Asia-Pacific Hematologic Malignancies Market Size by Region (2016-2027) 8.2 China 8.3 Japan 8.4 South Korea 8.5 Southeast Asia 8.6 India 8.7 Australia 8.8 Rest of Asia-Pacific 9 Latin America 9.1 Latin America Hematologic Malignancies Market Size by Country (2016-2027) 9.2 Mexico 9.3 Brazil 9.4 Rest of Latin America 10 Middle East & Africa 10.1 Middle East & Africa Hematologic Malignancies Market Size by Country (2016-2027) 10.2 Turkey 10.3 Saudi Arabia 10.4 UAE 10.5 Rest of Middle East & Africa 11 Hematologic Malignancies Market Dynamics 11.1 Hematologic Malignancies Industry Trends 11.2 Hematologic Malignancies Market Drivers 11.3 Hematologic Malignancies Market Challenges 11.4 Hematologic Malignancies Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Disclaimer 13.4 Author List

List of Tables Table 1. Global Market Hematologic Malignancies Market Size (US$ Million) Comparison by Region 2016 VS 2021 VS 2027 Table 2. Global Hematologic Malignancies Market Size by Region (2016-2021) & (US$ Million) Table 3. Global Hematologic Malignancies Market Size Share by Region (2016-2021) Table 4. Global Hematologic Malignancies Forecasted Market Size by Region (2022-2027) & (US$ Million) Table 5. Global Hematologic Malignancies Forecasted Market Size Share by Region (2022-2027) Table 6. Global Hematologic Malignancies Market Size (US$ Million) by Type: 2016 VS 2021 VS 2027 Table 7. Global Hematologic Malignancies Market Size by Type (2016-2021) & (US$ Million) Table 8. Global Hematologic Malignancies Revenue Market Share by Type (2016-2021) Table 9. Global Hematologic Malignancies Forecasted Market Size by Type (2022-2027) & (US$ Million) Table 10. Global Hematologic Malignancies Revenue Market Share by Type (2022-2027) Table 11. Global Hematologic Malignancies Market Size (US$ Million) by Application: 2016 VS 2021 VS 2027 Table 12. Global Hematologic Malignancies Market Size by Application (2016-2021) & (US$ Million) Table 13. Global Hematologic Malignancies Revenue Market Share by Application (2016-2021) Table 14. Global Hematologic Malignancies Forecasted Market Size by Application (2022-2027) & (US$ Million) Table 15. Global Hematologic Malignancies Revenue Market Share by Application (2022-2027) Table 16. Global Hematologic Malignancies Revenue (US$ Million) by Players (2016-2021) Table 17. Global Hematologic Malignancies Revenue Market Share by Players (2016-2021) Table 18. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hematologic Malignancies as of 2020) Table 19. Date of Key Manufacturers Enter into Hematologic Malignancies Market Table 20. Global Hematologic Malignancies Top Players Headquarters and Area Served Table 21. Hematologic Malignancies Product Solution and Service Table 22. Global Hematologic Malignancies Players Market Concentration Ratio (CR5 and HHI) Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Pfizer, Inc. Basic Information List Table 25. Pfizer, Inc. Description and Business Overview Table 26. Pfizer, Inc. Hematologic Malignancies Products, Services and Solutions Table 27. Revenue (US$ Million) in Hematologic Malignancies Business of Pfizer, Inc. (2016-2021) Table 28. Pfizer, Inc. Recent Developments Table 29. F. Hoffmann-LA Roche ltd Basic Information List Table 30. F. Hoffmann-LA Roche ltd Description and Business Overview Table 31. F. Hoffmann-LA Roche ltd Hematologic Malignancies Products, Services and Solutions Table 32. Revenue (US$ Million) in Hematologic Malignancies Business of F. Hoffmann-LA Roche ltd (2016-2021) Table 33. F. Hoffmann-LA Roche ltd Recent Developments Table 34. Sanofi-Aventis Basic Information List Table 35. Sanofi-Aventis Description and Business Overview Table 36. Sanofi-Aventis Hematologic Malignancies Products, Services and Solutions Table 37. Revenue (US$ Million) in Hematologic Malignancies Business of Sanofi-Aventis (2016-2021) Table 38. Sanofi-Aventis Recent Developments Table 39. Bristol-Myers Squibb Company Basic Information List Table 40. Bristol-Myers Squibb Company Description and Business Overview Table 41. Bristol-Myers Squibb Company Hematologic Malignancies Products, Services and Solutions Table 42. Revenue (US$ Million) in Hematologic Malignancies Business of Bristol-Myers Squibb Company (2016-2021) Table 43. Bristol-Myers Squibb Company Recent Developments Table 44. AbbVie, Inc. Basic Information List Table 45. AbbVie, Inc. Description and Business Overview Table 46. AbbVie, Inc. Hematologic Malignancies Products, Services and Solutions Table 47. Revenue (US$ Million) in Hematologic Malignancies Business of AbbVie, Inc. (2016-2021) Table 48. AbbVie, Inc. Recent Developments Table 49. Novartis AG Basic Information List Table 50. Novartis AG Description and Business Overview Table 51. Novartis AG Hematologic Malignancies Products, Services and Solutions Table 52. Revenue (US$ Million) in Hematologic Malignancies Business of Novartis AG (2016-2021) Table 53. Novartis AG Recent Developments Table 54. GlaxoSmithKline PLC Basic Information List Table 55. GlaxoSmithKline PLC Description and Business Overview Table 56. GlaxoSmithKline PLC Hematologic Malignancies Products, Services and Solutions Table 57. Revenue (US$ Million) in Hematologic Malignancies Business of GlaxoSmithKline PLC (2016-2021) Table 58. GlaxoSmithKline PLC Recent Developments Table 59. Celgene Corporation Basic Information List Table 60. Celgene Corporation Description and Business Overview Table 61. Celgene Corporation Hematologic Malignancies Products, Services and Solutions Table 62. Revenue (US$ Million) in Hematologic Malignancies Business of Celgene Corporation (2016-2021) Table 63. Celgene Corporation Recent Developments Table 64. Johnson & Johnson Services, Inc. Basic Information List Table 65. Johnson & Johnson Services, Inc. Description and Business Overview Table 66. Johnson & Johnson Services, Inc. Hematologic Malignancies Products, Services and Solutions Table 67. Revenue (US$ Million) in Hematologic Malignancies Business of Johnson & Johnson Services, Inc. (2016-2021) Table 68. Johnson & Johnson Services, Inc. Recent Developments Table 69. Takeda Pharmaceutical Company limited Basic Information List Table 70. Takeda Pharmaceutical Company limited Description and Business Overview Table 71. Takeda Pharmaceutical Company limited Hematologic Malignancies Products, Services and Solutions Table 72. Revenue (US$ Million) in Hematologic Malignancies Business of Takeda Pharmaceutical Company limited (2016-2021) Table 73. Takeda Pharmaceutical Company limited Recent Developments Table 74. North America Hematologic Malignancies Market Size by Country (2016-2021) & (US$ Million) Table 75. North America Hematologic Malignancies Market Size by Country (2022-2027) & (US$ Million) Table 76. Europe Hematologic Malignancies Market Size by Country (2016-2021) & (US$ Million) Table 77. Europe Hematologic Malignancies Market Size by Country (2022-2027) & (US$ Million) Table 78. Asia-Pacific Hematologic Malignancies Market Size by Region (2016-2021) & (US$ Million) Table 79. Asia-Pacific Hematologic Malignancies Market Size by Region (2022-2027) & (US$ Million) Table 80. Asia-Pacific Hematologic Malignancies Market Share by Region (2016-2021) Table 81. Asia-Pacific Hematologic Malignancies Market Share by Region (2022-2027) Table 82. Latin America Hematologic Malignancies Market Size by Country (2016-2021) & (US$ Million) Table 83. Latin America Hematologic Malignancies Market Size by Country (2022-2027) & (US$ Million) Table 84. Middle East & Africa Hematologic Malignancies Market Size by Players (2016-2021) & (US$ Million) Table 85. Middle East & Africa Hematologic Malignancies Market Size by Country (2022-2027) & (US$ Million) Table 86. Hematologic Malignancies Market Trends Table 87. Hematologic Malignancies Market Drivers Table 88. Hematologic Malignancies Market Challenges Table 89. Hematologic Malignancies Market Restraints Table 90. Research Programs/Design for This Report Table 91. Key Data Information from Secondary Sources Table 92. Key Data Information from Primary Sources List of Figures Figure 1. Global Hematologic Malignancies Market Size Year-over-Year 2016-2027 & (US$ Million) Figure 2. Global Hematologic Malignancies Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 3. Global Hematologic Malignancies Market Share by Regions: 2021 VS 2027 Figure 4. Global Hematologic Malignancies Forecasted Market Size Share by Region (2022-2027) Figure 5. North America Hematologic Malignancies Market Size (US$ Million) Growth Rate (2016-2027) Figure 6. Europe Hematologic Malignancies Market Size (US$ Million) and Growth Rate (2016-2027) Figure 7. Asia-Pacific Hematologic Malignancies Market Size (US$ Million) and Growth Rate (2016-2027) Figure 8. Latin America Hematologic Malignancies Market Size (US$ Million) and Growth Rate (2016-2027) Figure 9. Middle East & Africa Hematologic Malignancies Market Size (US$ Million) and Growth Rate (2016-2027) Figure 10. Global Hematologic Malignancies Market Size Share by Type in 2021 & 2027 Figure 11. Leukemia Market Size (US$ Million) YoY Growth (2016-2027) Figure 12. Lymphoma Market Size (US$ Million) YoY Growth (2016-2027) Figure 13. Multiple Myeloma Market Size (US$ Million) YoY Growth (2016-2027) Figure 14. Others Market Size (US$ Million) YoY Growth (2016-2027) Figure 15. Global Hematologic Malignancies Market Size Share by Application in 2021 & 2027 Figure 16. Chemotherapy Market Size (US$ Million) YoY Growth (2016-2027) Figure 17. Radiotherapy Market Size (US$ Million) YoY Growth (2016-2027) Figure 18. Immunotherapy Market Size (US$ Million) YoY Growth (2016-2027) Figure 19. Stem Cell Transplantation Market Size (US$ Million) YoY Growth (2016-2027) Figure 20. Others Market Size (US$ Million) YoY Growth (2016-2027) Figure 21. Hematologic Malignancies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020 Figure 22. Global Top 5 and Top 10 Players Hematologic Malignancies Market Share in 2020 Figure 23. North America Hematologic Malignancies Market Share by Country (2016-2027) Figure 24. United States Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 25. Canada Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 26. Germany Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 27. France Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 28. U.K. Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 29. Italy Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 30. Russia Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 31. Nordic Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 32. Rest of Europe Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 33. Asia-Pacific Hematologic Malignancies Market Share by Region (2016-2027) Figure 34. China Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 35. Japan Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 36. South Korea Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 37. Southeast Asia Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 38. India Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 39. Australia Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 40. Rest of Asia-Pacific Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 41. Latin America Hematologic Malignancies Market Share by Country (2016-2027) Figure 42. Mexico Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 43. Brazil Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 44. Rest of Latin America Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 45. Middle East & Africa Hematologic Malignancies Market Share by Country (2016-2027) Figure 46. Turkey Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 47. Saudi Arabia Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 48. UAE Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 49. Rest of Middle East & Africa Hematologic Malignancies Market Size (2016-2027) & (US$ Million) Figure 50. Bottom-up and Top-down Approaches for This Report Figure 51. Data Triangulation

Pfizer, Inc. F. Hoffmann-LA Roche ltd Sanofi-Aventis Bristol-Myers Squibb Company AbbVie, Inc. Novartis AG GlaxoSmithKline PLC Celgene Corporation Johnson & Johnson Services, Inc. Takeda Pharmaceutical Company limited